Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Vertex Pharmaceuticals Cash Provided by (Used in) Financing Activity, Including Discontinued Operation decreased by 597.9% to -$538.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.8%, from -$680.40M to -$538.80M. Over 3 years (FY 2021 to FY 2025), Cash Provided by (Used in) Financing Activity, Including Discontinued Operation shows a downward trend with a 14.4% CAGR.
Analysis
How to read this metric
Negative values often indicate debt repayment or significant share buybacks, while positive values suggest capital raising through debt or equity issuance.
Detailed definition
The net cash flow resulting from transactions with equity and debt holders, including share repurchases, dividend paymen...
Peer comparison
Standard line item in the Statement of Cash Flows for all public companies.
other_net_cash_provided_by_used_in_financing_activitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$656.70M | -$336.20M | -$95.40M | -$60.20M | -$140.55M | -$140.55M | -$140.55M | -$140.55M | -$357.50M | -$358.60M | -$387.50M | -$391.30M | -$680.40M | -$349.20M | -$1.15B | -$77.20M | -$538.80M |
| QoQ Change | — | — | +48.8% | +71.6% | +36.9% | -133.5% | +0.0% | +0.0% | +0.0% | -154.4% | -0.3% | -8.1% | -1.0% | -73.9% | +48.7% | -230.6% | +93.3% | -597.9% |
| YoY Change | — | — | — | — | +90.8% | -47.3% | — | -133.5% | — | -154.4% | -155.1% | -175.7% | -178.4% | -90.3% | +2.6% | -197.9% | +80.3% | +20.8% |
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Vertex Pharmaceuticals (VRTX) reported cash provided by (used in) financing activity, including discontinued operation of -$538.80M in Q1 2026.
- How has Vertex Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Vertex Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 20.8% year-over-year, from -$680.40M to -$538.80M.
- What is the long-term trend for Vertex Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a 14.4% compound annual growth rate (CAGR), from -$1.51B to -$2.26B.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- The net cash flow resulting from debt and equity transactions with investors.